Mulberry Leaf Extract and Blood Glucose Control in Diabetics
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Mulberry leaf teas or extracts are used as a natural remedy for diabetes in some countries. Animal studies have shown some effect of mulberry leaf extract on blood glucose. The purpose of this trial is to assess the effect of mulberry leaf extract on type 2 diabetics, by measuring blood glucose two hours after eating a meal and taking a capsule containing either mulberry leaf extract or a placebo.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus Type 2 |
Dietary Supplement: Mulberry leaf extract effect on post prandial blood glucose |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Randomized Double Blind Cross Over Trial to Examine the Effect of Mulberry Leaf Extract on Post Prandial Glucose in Type 2 Diabetics |
- change in 2 hour post prandial blood glucose [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]Success would be a change in pc glucose of -1.5 units (SI) greater than 70% of the time or in more than 70% of subject, and no increased incidence of hypoglycemia with the intervention
- number of subjects with adverse changes in creatinine, AST, ALT, and blood pressure due to intervention [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]Because mulberry leaf tea has been shown to contain cadmium which can have renal or hepatotoxic effects, renal function, liver function, and blood pressure will be monitored.
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: Mulberry leaf extract effect on post prandial blood glucose
Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.
Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications.
Patients will participate in a double blind randomized cross over trial for 6 weeks. Four 2 weeks, half of the type 2 diabetic patients will receive mulberry leaf capsules three times per day with meals (made from Mulberry Zuccarin tablets - New Nordic, 400 mg of mulberry leaf extract per tablet) and half will receive placebo capsules. Following a one week wash out period, the treatments administered to each group will be reversed for the next 2 weeks, and data will continue to be gathered for a final wash out week. Patients will keep a diary of food, exercise, and fasting glucose each morning as well as at least one 2 hour pc glucose each day. Weight, hemoglobin A1C, liver function tests, and renal function tests will be done at baseline and at the end of the 6 weeks. As well, blood pressure will be monitored when the 2 weekly batches of medication are distributed, and at the end of the 6 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 diabetes
- baseline hemoglobin A1C greater than or equal to 7.5 or fasting glucose greater than 7 (SI units)
Exclusion Criteria:
- on insulin
- history of hepatic or renal disease
- pregnant or nursing women
Contacts and Locations| Contact: Nancy V Craig, MDCM | 780 443-0200 | wncraig@telusplanet.net |
| Canada, Alberta | |
| Hope Medical Clinic | Not yet recruiting |
| Edmonton, Alberta, Canada, T5B 2Y1 | |
| Contact: Nancy V Craig, MDCM 780-479-1944 wncraig@telusplanet.net | |
| Principal Investigator: Nancy V Craig, MDCM | |
| Principal Investigator: | Nancy V Craig, MDCM | |
| Study Director: | William R Craig, MD CM | University of Alberta |
More Information
Additional Information:
Publications:
| Responsible Party: | Dr. Nancy Craig, unaffiliated |
| ClinicalTrials.gov Identifier: | NCT01305434 History of Changes |
| Other Study ID Numbers: | MLE-DM2 |
| Study First Received: | February 24, 2011 |
| Last Updated: | March 1, 2011 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Craig, Nancy, M.D.:
|
diabetes mellitus type 2 mulberry leaf extract post prandial blood glucose |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013